Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Baricitinib in Rheumatoid Arthritis
jRCT2080222355Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in rheumatoid arthritis (RA) comparing Baricitinib once daily with Placebo once daily (2 arms). Status: unknown.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080222355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222355.